Scinai Immunotherapeutics Ltd. American Depositary Shares
SCNI
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
Last trade$0.3999
Day change-$0.0042 (-1.04%)
Day range$0.354 – $0.412
Volume38,423
Market cap$1M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for SCNI.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for SCNI.
Recent news
Company coverage with links to the original publishers.
Scinai Immunotherapeutics will lead a roundtable discussion at the 7th Dermatology Drug Development Summit Europe in Amsterdam, exploring how oral peptide and small molecule therapies may complement, compete with, or displace injectable biologic therapies in immunology and dermatology. The discussion will address key challenges including pharmacokinetic variability, bioavailability, treatment adherence, and the evolving balance between efficacy and convenience in immunotherapy development.
Scinai Immunotherapeutics (NASDAQ: SCNI) received a Nasdaq notification on March 12, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share, as its closing bid price fell below this threshold for 30 consecutive business days. The company has been given 180 calendar days (until September 8, 2026) to regain compliance. If the stock closes at or above $1.00 for ten consecutive business days during this period, Nasdaq will confirm compliance and close the matter.
Scinai Immunotherapeutics published research validating PC111, a novel monoclonal antibody targeting pemphigus and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), demonstrating potential as a disease-modifying therapy with a unique non-immunosuppressive mechanism.
Scinai Immunotherapeutics has regained full compliance with Nasdaq's listing requirements after converting $29 million of debt into equity, leaving a debt balance of $273,000. This clears the path for the company to focus on its R&D programs and CDMO business unit.
JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced receipt of a letter from the Nasdaq Stock Market ("Nasdaq") dated November 1, 2023, regarding non-compliance with the requirement to maintain a minimum bid price of $1.00 per share.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.